| Overview |
| bs-13830R |
| CELF3 Polyclonal Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
| Human |
| Mouse, Rat, Cow, Pig, Chicken |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CELF3 |
| 401-465/465 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 11189 |
| Q5SZQ8 |
| Cytoplasm, Nucleus |
| Bruno-like protein 1; BRUNOL1; CAG repeat protein 4; CAGH4; CELF-3; CELF3; CELF3_HUMAN; CUG-BP- and ETR-3-like factor 3; CUGBP Elav-like family member 3; ELAV-type RNA-binding protein 1; ERDA4; ETR-1; Expanded repeat domain protein CAG/CTG 4; RNA-binding protein BRUNOL-1; TNRC4; Trinucleotide repeat-containing gene 4 protein. |
| RNA-binding protein involved in the regulation of pre-mRNA alternative splicing. Mediates exon inclusion and/or exclusion in pre-mRNA that are subject to tissue-specific and developmentally regulated alternative splicing. Specifically activates exon 5 inclusion of cardiac isoforms of TNNT2 during heart remodeling at the juvenile to adult transition. Binds to muscle-specific splicing enhancer (MSE) intronic sites flanking the alternative exon 5 of TNNT2 pre-mRNA. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
| ICC |
1:100-500 |
Powered by Bioz